RxDoctor Payments Data

Lloyd Smith, MD

Ophthalmology · Natchez, MSNPI 1639192750

Payments from drug & device makers

$2,604in general payments, 2019–2025

Across 99 payments — averaging $26.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$619
  • Alcon$538
  • Glaukos Corporation$418
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$172
  • Regeneron Healthcare Solutions, Inc.$125
  • Aerie Pharmaceuticals, Inc.$119
  • plus $613 from 14 others

What the payments were for

  • Food & beverage$2,50496%
  • Education$1004%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,604 in reported general payments places this provider in the 55th percentile of 150 ophthalmology providers in Mississippi.

See all ophthalmology providers in Mississippi

Medicare billing

Part B allowed, 2024
$673,860
Medicare patients
1,507
Services billed
5,601

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost154$59,785
CombiganBrimonidine Tartrate/Timolol108$29,812
RocklatanNetarsudil Mesylat/Latanoprost80$29,048
Prednisolone Acetate354$20,597
Latanoprost1,182$9,585
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol47$7,578
SimbrinzaBrinzolamide/Brimonidine Tart31$7,069
RhopressaNetarsudil Mesylate13$6,185
Alphagan PBrimonidine Tartrate21$5,931
Fluorometholone59$4,922
Ketorolac Tromethamine192$4,489
Brimonidine Tartrate354$4,036
Ofloxacin211$3,485
Timolol Maleate321$3,473
Lotemax SmLoteprednol Etabonate13$3,204

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan, Alphagan P$619$95,528283 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$119$35,23393 claims
AlconSimbrinza$538$7,06931 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm$172$3,20413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 150 ophthalmology providers in Mississippi.

Other ophthalmology in Natchez

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →